A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

Cancer

Volumn 112, Issue 2, 2008, Pages 331-339

  Downs Jr , Levi S ^a   Judson, Patricia L ^a   Argenta, Peter A ^a   Ghebre, Rahel ^a   Geller, Melissa A ^a   Bliss, Robin L ^b   Boente, Matthew P ^c   Nahhas, William A ^d   Abu Ghazaleh, Samir Z ^e   Chen, M Dwight ^f   Carson, Linda F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Minnesota Oncology Hematology PA ^*  (United States)

^d WRIGHT STATE UNIVERSITY   (United States)

^e Avera Health   (United States)

^f Center for Gynecologic Oncology and Pelvic Surgery   (United States)

Author keywords

Angiogenesis inhibitor; Phase 2 trial; Platinum sensitivity; Recurrent ovarian cancer; System for Thalidomide Education and Prescribing Safety

Indexed keywords

CA 125 ANTIGEN; THALIDOMIDE; TOPOTECAN;

ADULT; ANEMIA; ARTICLE; BLEEDING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHI SQUARE TEST; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ENDOCRINE DISEASE; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HEARING DISORDER; HUMAN; IMMUNOMODULATION; INFECTION; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PAIN; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT CANCER; SKIN TOXICITY; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; THALIDOMIDE; TOPOTECAN;

EID: 38049027230     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23164     Document Type: Article

References (27)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, Ga: American Cancer Society; 2006.
2. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metobolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971-978.
3. Moreira AL, Sampaio EP, Zmuidzinas A. Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J Exp Med. 1993;177:1675-1680.
4. Richardson P, Hidershima T, Anderson K. Thalidomide: emerging role in cancer medicine. Annu Rev Med. 2002;53: 629-657.
5. Corral LG, Muller GW, Moreira AL, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor-α inhibitory activity. Mol Med. 1996;2:506-515.
6. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885-1892.
7. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules, involved in the adhesion cascade. Immunopharmocology. 1996;31:213-221.
8. Kobayashi H, Yagyu T, Kondo T, et al. Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination. Cancer Res. 2005;65:10464-10471.
9. Clements M, Jones C, Cumming M, et al. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol. 1999;44:411-416.
10. Armstrong DK. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist. 2004;9:33-42.
11. Therasse P, Arbudk SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
12. Guppy AE, Rustin GJ. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist. 2002;7:437-443.
13. Ciaravino G, Vela A, Roberts J, Teng NNH. Thalidomide treatment of ovarian carcinoma - a preliminary analysis. Presented at the 29th Annual Meeting of the Western Association of Gynecological Oncologists, May 24-27, 2000, Monterey, California.
14. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol. 1996;14:3056-3061.
15. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
16. Goldman AI, Hannan PJ. Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm. Stat Med. 2001;20:1575-1589.
17. Prasad HK, Kaushal V, Mehta P. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature. Am J Hematol. 2007;82:855-857.
18. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. Thromb Haemost. 2007;97:1031-1036.
19. Chan JK, Manuel MR, Ciaravino G, et al. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. Gynecol Oncol. 2006;103:919-923.
20. Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000;82:812-817.
21. Short SC, Traish D, Dowe A, et al. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol. 2001; 51:41-45.
22. Marx GM, Pavlakis N, McCowatt S, et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2001;54:31-38.
23. Fine HA, Wen P-Y, Maher EA, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high grade gliomas. J Clin Oncol. 2003;21:2299-2304.
24. Drake MJ, Robson W, Mehta P, et al. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003;24:822-827.
25. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001;7:1888-1893.
26. Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol. 2001;28(4Suppl 15):62-66.
27. Heere-Ress E, Boehm J, Thallinger C, et al. Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. J Invest Dermatol. 2005;125:201-206.